Green Cross’s U.S. partner gets 'orphan drug' designation for novel anticancer drug

Published: 2013-05-14 06:58:00

Updated: 2013-05-14 06:58:00

Green Cross Corp. said last Friday that JX-594 (pexastimogene devacirepvec), an investigational medicine its U.S. business partner Jennerex Biotherapeutics developed for patients suffering from hepatocellular carcinoma (HCC), has been designated as an orphan drug by the United States Food and Dru...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK